Trials / Completed
CompletedNCT00037596
Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
A Dose Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) Given in Combination With Cytarabine in Relapsed or Refractory Patients and Alder De Novo Patients With Acute Myeloid Leukemia.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives are a) to establish the maximum tolerated dose of gemtuzumab ozogamicin in combination with cytarabine and b) to assess the safety of gemtuzumab ozogamicin when given concurrently with cytarabine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemtuzumab Ozogamicin | |
| DRUG | cytarabine. |
Timeline
- Start date
- 2000-08-01
- Primary completion
- 2003-04-01
- Completion
- 2003-04-01
- First posted
- 2002-05-20
- Last updated
- 2013-02-13
Source: ClinicalTrials.gov record NCT00037596. Inclusion in this directory is not an endorsement.